Dimercaprol: The Classic Chelator in Heavy Metal Poisoning – Pharmacology, Clinical Use, and Safety

In the emergency department, a patient arrives with a burning sensation in the gums, tremors, and a metallic taste that has persisted for days. The history reveals accidental ingestion of a poorly labeled pesticide containing arsenic trioxide. Within hours, the patient’s liver enzymes skyrocket, and the clinician must decide between supportive care and a life‑saving antidote. Dimercaprol, the first chelating agent approved by the FDA for heavy‑metal poisoning, remains the gold standard for arsenic, mercury, and thallium exposures. Its unique pharmacology, historical significance, and practical challenges make it a cornerstone of toxicology practice and a frequent subject of board examinations. This article delves into the science behind dimercaprol, its clinical applications, safety profile, and key points every pharmacy or medical student should master.

Introduction and Background

Dimercaprol, also known as British anti‑arsenical (BAL) or 2,3‑bis(mercapto)propane‑1,3‑diol, was first synthesized in 1938 by the British chemist William R. P. G. Smith as a potential antidote for arsenic‑based pesticides, which led to a surge in acute arsenic intoxication cases. In the 1950s, the U.S. Army adopted dimercaprol for treating soldiers exposed to arsenic and other heavy metals during warfare. The drug’s name, “British anti‑arsenical,” reflects its origin and primary indication.

From a pharmacological standpoint, dimercaprol belongs to the class of sulfhydryl (thiol) chelators. It contains two free sulfhydryl groups capable of forming strong coordinate covalent bonds with divalent and trivalent metal ions such as arsenic (As³⁺), mercury (Hg²⁺), and thallium (Tl⁺). By sequestering these metals, dimercaprol prevents them from interacting with cellular macromolecules, thereby reducing oxidative stress, enzyme inhibition, and DNA damage. Though newer chelators like DMSA and succimer have largely supplanted dimercaprol for routine outpatient management, it remains indispensable in severe, life‑threatening exposures, especially when rapid intervention is required.

Despite its age, dimercaprol’s mechanism of action, pharmacokinetics, and safety profile provide a rich educational framework for understanding chelation therapy. Moreover, its continued use in modern toxicology underscores the importance of mastering its nuances, from dosing schedules to monitoring protocols, in both academic and clinical settings.

Mechanism of Action

1. Chelation Chemistry

Dimercaprol’s core activity is chemical chelation. The molecule’s two sulfhydryl groups (–SH) act as hard Lewis bases that preferentially bind to hard Lewis acids like arsenic and thallium. The resulting 1:1 metal‑ligand complexes are highly stable (log K values > 10 for As³⁺), rendering the metals biologically inactive and facilitating renal excretion. The chelation process also reduces the metals’ ability to generate reactive oxygen species (ROS) via Fenton‑type reactions, thereby mitigating oxidative damage to lipids, proteins, and nucleic acids.

2. Inhibition of Metal‑Dependent Enzymes

Arsenic and mercury exert toxicity partly by binding to sulfhydryl groups of enzymes such as pyruvate dehydrogenase and catalase, leading to metabolic derangements. Dimercaprol’s high affinity for these metals means it can competitively displace them from enzyme active sites. For example, in arsenic poisoning, dimercaprol restores pyruvate dehydrogenase activity, normalizing lactate‑to‑pyruvate ratios and improving cellular respiration.

3. Modulation of Redox Status

By chelating metals that participate in redox cycling, dimercaprol indirectly preserves the activity of antioxidant systems like glutathione peroxidase. Additionally, the drug’s own sulfhydryl groups can act as mild reducing agents, scavenging free radicals and protecting cellular membranes during acute exposure.

4. Pharmacokinetic Considerations of Chelation

Once bound to dimercaprol, metals are rendered less lipophilic, enhancing renal filtration. The drug’s own hydrophilic nature ensures that the metal‑dimercaprol complexes are rapidly cleared via the kidneys, a process that is further accelerated by the drug’s high plasma protein binding (≈ 90 %) and distribution into extracellular fluid.

Clinical Pharmacology

Dimercaprol is administered intramuscularly (IM) or intravenously (IV) due to its poor oral bioavailability. The drug is prepared as a 20 % solution in sterile water for injection, typically diluted to a 10 % working concentration for clinical use.

Pharmacokinetics

Because of its rapid distribution and elimination, dimercaprol requires frequent dosing to maintain therapeutic chelating capacity. The drug’s high protein binding also necessitates careful monitoring in patients with hypo‑albuminemia, as free drug concentrations may rise, increasing toxicity risk.

Pharmacodynamics

Clinical efficacy is dose‑dependent and correlates with the rate of metal clearance. The standard therapeutic window is achieved with a loading dose of 80 mg IM followed by 80 mg every 6–8 h for 24–48 h, depending on the severity of exposure. The drug’s half‑life mandates that dosing intervals be shorter than 6 h to prevent sub‑therapeutic chelation during critical periods.

In vitro studies demonstrate that dimercaprol can reduce arsenic bioavailability by up to 70 % when administered within the first 4 h of exposure. Delays beyond 12 h diminish chelation efficiency, underscoring the importance of early intervention.

Therapeutic Applications

• Arsenic poisoning (acute and chronic) – 80 mg IM every 6 h; loading dose 80 mg IM, then 80 mg q6‑8 h for 24–48 h
• Mercury (especially inorganic mercury) poisoning – 80 mg IM q6‑8 h; total duration 48–72 h
• Thallium poisoning – 80 mg IM q6‑8 h; total duration 24–48 h
• Organophosphate poisoning (as an adjunct) – 80 mg IM q6‑8 h; used when metallic poisoning suspected

Off‑label uses include:

1. Chelation of lead in severe occupational exposures when other agents are contraindicated.
2. Adjunct therapy in severe cyanide poisoning to reduce oxidative damage.
3. Use in cases of combined metal and organophosphate exposure to mitigate synergistic toxicity.

Special populations:

• Pediatric – Dose adjusted to 0.5–1 mg/kg IM q6‑8 h; careful monitoring for hypotension.
• Geriatric – Reduced renal clearance may necessitate extended dosing intervals; monitor for orthostatic hypotension.
• Renal/hepatic impairment – No dose adjustment needed for mild to moderate impairment, but monitor renal function closely; use caution in severe renal failure.
• Pregnancy – Category C; use only when benefits outweigh risks; avoid in first trimester if possible.

Adverse Effects and Safety

Dimercaprol’s side effect profile is dominated by its potent vasodilatory and irritant properties.

• Hypotension – 30–40 % incidence; may be severe in patients with volume depletion.
• Bruising at injection site – 20–30 % incidence; can be minimized with proper needle technique.
• Gastrointestinal upset – nausea, vomiting 10–15 %.
• Allergic reactions – rash, urticaria, anaphylaxis < 1 %.
• Methemoglobinemia – rare (< 1 %); monitor pulse oximetry in severe cases.

Black box warnings: Severe hypotension and anaphylaxis; caution in patients with cardiovascular disease.

Drug Interactions

Monitoring parameters include serum creatinine, blood pressure, heart rate, and complete blood count. Contraindications: known hypersensitivity to dimercaprol, severe cardiovascular disease, uncontrolled hypertension, and pregnancy (first trimester).

Clinical Pearls for Practice

• Start Early: Initiate dimercaprol within 4 h of exposure for optimal chelation; delays reduce efficacy.
• Dosing Schedule: Use 80 mg IM q6‑8 h; avoid longer intervals to maintain therapeutic levels.
• Volume Status Matters: Ensure adequate IV fluids to mitigate hypotension; consider vasopressors if needed.
• Injection Technique: Use a 23–25 G needle, aspirate before injection to avoid intravascular administration.
• Monitor for Hypotension: Check vitals every 15 min during the first 2 h of therapy.
• Adjunctive Therapy: Pair with atropine and pralidoxime in organophosphate cases; avoid when only metal poisoning is present.
• Drug‑Drug Interaction Awareness: Avoid concurrent use of sulfhydryl‑containing antibiotics; adjust dosing accordingly.

Comparison Table

Exam‑Focused Review

Common Question Stem: A 32‑year‑old farmer presents with abdominal pain, metallic taste, and elevated liver enzymes after ingesting a pesticide. Which antidote is most appropriate?

Answer: Dimercaprol (BAL) – the classic chelator for arsenic poisoning.

Key Differentiators:

• Dimercaprol vs DMSA – Dimercaprol requires IM/IV administration and causes hypotension; DMSA is oral and better tolerated.
• Dimercaprol vs DMPS – DMPS can be given orally; dimercaprol is faster acting but more toxic.
• Dimercaprol vs Penicillamine – Penicillamine chelates copper, not arsenic.

Must‑Know Facts:

1. Dimercaprol’s half‑life is 1–3 h; dosing must be every 6 h.
2. Hypotension is the most common adverse effect; treat with IV fluids.
3. Use only when exposure is confirmed or highly suspected; not for mild chronic exposure.
4. Pregnancy Category C; avoid first trimester if possible.
5. Monitor serum creatinine and blood pressure closely.

Key Takeaways

1. Dimercaprol is the first‑line chelator for acute arsenic, mercury, and thallium poisoning.
2. Its mechanism relies on thiol chelation that prevents metal‑induced enzyme inhibition and oxidative damage.
3. Administer IM or IV; dosing is 80 mg q6‑8 h with a loading dose of 80 mg.
4. Hypotension and injection site bruising are the most frequent adverse events.
5. Early initiation (< 4 h) is critical for maximal efficacy.
6. Co‑administration with sulfhydryl antibiotics or ACE inhibitors increases risk of toxicity.
7. Monitor vitals every 15 min during the first 2 h and adjust fluids accordingly.
8. Dimercaprol is contraindicated in severe cardiovascular disease and first‑trimester pregnancy.

Always consider the balance between rapid chelation and the drug’s hemodynamic effects; patient safety hinges on vigilant monitoring and timely fluid resuscitation.